Issue of Equity

RNS Number : 1140G

Oncimmune Holdings PLC

13 March 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Issue of Equity

On 19 March 2019, the Company announced the acquisition of Protagen Diagnostics AG, a leader in personalised immune-profiling (the "Acquisition").

The consideration for the Acquisition, of up to £4.11m, was to be satisfied by the allotment of up to 2,635,910 ordinary shares of 1p each in the Company at a price of 156p per share ("Consideration Shares") as follows:

· 1,623,890 Consideration Shares on completion of the transaction ("Completion"). Such shares were allotted and then admitted to trading on AIM on 25 March 2019;

· 374,744 Consideration Shares if Protagen signed revenue-generating contracts to the aggregate value of at least EUR 0.5 million in the period ending 28 February 2020 ("Tranche 1 Deferred Shares");

· 249,830 Consideration Shares if certain named key employees of Protagen remain employed by the enlarged group 12 months after Completion ("Tranche 2 Deferred Shares"); and

· 387,447 Consideration Shares on the date falling 24 months after the Completion date (and which was to be available to offset any warranty and indemnity claims under the acquisition agreement) ("Tranche 3 Deferred Shares").

In relation to the Tranche 2 Deferred Shares, the key employees referenced above have remained employed by the enlarged group for 12 months after Completion and as this condition has been satisfied, the Tranche 2 Deferred Shares have been allotted by the Company conditional on Admission. Accordingly, application has been made for 249,830 Consideration Shares to be admitted to trading on AIM and dealings in those Consideration Shares are expected to commence on 19 March 2020. The new Consideration Shares will, when issued, rank pari passu with the existing ordinary shares of the Company.  

The determination of the number of Tranche 1 Deferred Shares (if any) is yet to be finalised and therefore an announcement in relation thereto and in relation to the Tranche 3 Deferred Shares will be made in due course.

Following admission of the Tranche 2 Deferred Shares, the total number of ordinary shares and voting rights in the Company will be 63,500,047. The Company does not hold any shares in treasury.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time 

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit    www.oncimmune.com

 

END

 

 

IOEFXLFFBXLZBBB